{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-000587","form_type":"8-K","ticker":"BDPT","cik":"0001575142","company_name":"BIOADAPTIVES, INC.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.473089+00:00","generated_at":"2026-06-17T05:08:59.983227+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioAdaptives appoints Dr. Yaguang Liu to board and increases authorized shares to 1.25 billion","bullets":["Dr. Yaguang Liu appointed to board effective April 5, 2023; holds 32 US patents on natural botanicals.","Authorized common stock increased from 750M to 1.25B shares; preferred shares authorized at 10M.","Amendment approved by board and majority shareholders on March 6, 2023, effective March 27, 2023.","Dr. Liu is founder of L.Y. Research Corp and has experience with FDA IND applications and clinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-000587","json":"https://secwatch.observer/filing/0001640334-23-000587.json","markdown":"https://secwatch.observer/filing/0001640334-23-000587.md","text":"https://secwatch.observer/filing/0001640334-23-000587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575142/000164033423000587/0001640334-23-000587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575142/000164033423000587/bdpt_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:08:59.983227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e23cf14c0","claim":"Dr. Yaguang Liu was appointed as Board of Directors at BIOADAPTIVES, INC..","evidence_excerpt":"On April 5, 2023, the Company appointed Dr. Yaguang Liu to its Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1575142/000164033423000587/0001640334-23-000587-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"932be19b34b8b51dacfcc52dade2ab7490de0533","claim":"BIOADAPTIVES, INC.: Amended Articles of Incorporation to increase authorized shares of common stock from 750,000,000 to 1,250,000,000 shares and authorize 10,000,000 preferred shares (effective 2023-03-27).","evidence_excerpt":"On March 6, 2023, the Company’s board and a majority of its shareholders approved an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of its common stock, par value .0001, from 750,000,000 shares to 1,250,000,000 shares of which 10,000,000 may be preferred shares. The increase became effective March 27, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1575142/000164033423000587/0001640334-23-000587-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-27"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}